Stock Observer logo

The Latest Headlines at Stock Observer

Image about Datadog (NASDAQ:DDOG) Insider Sells $2,810,002.00 in Stock

Datadog (NASDAQ:DDOG) Insider Sells $2,810,002.00 in Stock

Datadog, Inc. (NASDAQ:DDOG – Get Free Report) insider Yanbing Li sold 12,700 shares of the firm’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $221.26, for a total value... More of this article »
Image about Insider Selling: F5 (NASDAQ:FFIV) CTO Sells $1,815,368.16 in Stock

Insider Selling: F5 (NASDAQ:FFIV) CTO Sells $1,815,368.16 in Stock

F5, Inc. (NASDAQ:FFIV – Get Free Report) CTO Michael Montoya sold 4,426 shares of F5 stock in a transaction on Monday, September 14th. The shares were sold at an average price of $410.16, for a total transaction of $1,815,368.16.... More of this article »
Image about Schwab High Yield Bond ETF (NYSEARCA:SCYB) Hits New 1-Year Low  – Should You Sell?

Schwab High Yield Bond ETF (NYSEARCA:SCYB) Hits New 1-Year Low – Should You Sell?

Schwab High Yield Bond ETF (NYSEARCA:SCYB – Get Free Report)’s share price reached a new 52-week low on Wednesday . The company traded as low as $25.60 and last traded at $25.60, with a volume of 1190998 shares traded.... More of this article »
Image about Janus Henderson Short Duration Income ETF (NYSEARCA:VNLA) Hits New 12-Month Low  – Time to Sell?

Janus Henderson Short Duration Income ETF (NYSEARCA:VNLA) Hits New 12-Month Low – Time to Sell?

Janus Henderson Short Duration Income ETF (NYSEARCA:VNLA – Get Free Report)’s stock price hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $48.72 and last traded at $48.72, with a volume... More of this article »
Image about PGIM Active High Yield Bond ETF (NYSEARCA:PHYL) Hits New 52-Week Low  – Here’s Why

PGIM Active High Yield Bond ETF (NYSEARCA:PHYL) Hits New 52-Week Low – Here’s Why

Shares of PGIM Active High Yield Bond ETF (NYSEARCA:PHYL – Get Free Report) hit a new 52-week low during trading on Wednesday . The stock traded as low as $34.15 and last traded at $34.15, with a volume of 115702 shares. The... More of this article »
Image about JPMorgan Income ETF (NYSEARCA:JPIE) Hits New 1-Year Low  – Time to Sell?

JPMorgan Income ETF (NYSEARCA:JPIE) Hits New 1-Year Low – Time to Sell?

JPMorgan Income ETF (NYSEARCA:JPIE – Get Free Report) shares reached a new 52-week low during mid-day trading on Wednesday . The company traded as low as $45.30 and last traded at $45.31, with a volume of 2277255 shares changing... More of this article »
Image about Wingstop (NASDAQ:WING) Reaches New 1-Year Low  – Should You Sell?

Wingstop (NASDAQ:WING) Reaches New 1-Year Low – Should You Sell?

Wingstop Inc. (NASDAQ:WING – Get Free Report) shares hit a new 52-week low on Wednesday . The stock traded as low as $100.13 and last traded at $100.84, with a volume of 2887113 shares traded. The stock had previously closed... More of this article »
Image about Duolingo (NASDAQ:DUOL) vs. Coursera (NYSE:COUR) Critical Review

Duolingo (NASDAQ:DUOL) vs. Coursera (NYSE:COUR) Critical Review

Duolingo (NASDAQ:DUOL – Get Free Report) and Coursera (NYSE:COUR – Get Free Report) are both consumer discretionary companies, but which is the superior business? We will contrast the two companies based on the strength... More of this article »
Image about Joby Aviation, Inc. (NYSE:JOBY) Receives Average Rating of “Reduce” from Brokerages

Joby Aviation, Inc. (NYSE:JOBY) Receives Average Rating of “Reduce” from Brokerages

Shares of Joby Aviation, Inc. (NYSE:JOBY – Get Free Report) have earned an average rating of “Reduce” from the nine research firms that are presently covering the stock, Marketbeat Ratings reports. Three investment... More of this article »
Image about Replimune Group, Inc. (NASDAQ:REPL) Given Consensus Rating of “Moderate Buy” by Brokerages

Replimune Group, Inc. (NASDAQ:REPL) Given Consensus Rating of “Moderate Buy” by Brokerages

Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the ten ratings firms that are covering the company, MarketBeat Ratings reports. Two equities research... More of this article »
Image about Contrasting AGI (AGBK) and Its Competitors

Contrasting AGI (AGBK) and Its Competitors

AGI (NYSE:AGBK – Get Free Report) is one of 925 public companies in the “Banks” industry, but how does it weigh in compared to its competitors? We will compare AGI to related businesses based on the strength of its... More of this article »
Image about Direxion Daily CSI 300 China A Share Bear 1X Shares (NYSEARCA:CHAD) to Issue Dividend of $0.08

Direxion Daily CSI 300 China A Share Bear 1X Shares (NYSEARCA:CHAD) to Issue Dividend of $0.08

Direxion Daily CSI 300 China A Share Bear 1X Shares (NYSEARCA:CHAD – Get Free Report) announced a dividend on Wednesday, September 16th. Stockholders of record on Friday, October 30th will be paid a dividend of 0.0794 per share... More of this article »
Image about Grupo Bimbo, S.A.B. de C.V. (OTCMKTS:BMBOY) Short Interest Up 87.0% in August

Grupo Bimbo, S.A.B. de C.V. (OTCMKTS:BMBOY) Short Interest Up 87.0% in August

Grupo Bimbo, S.A.B. de C.V. (OTCMKTS:BMBOY – Get Free Report) was the target of a large growth in short interest during the month of August. As of August 31st, there was short interest totaling 316 shares, a growth of 87.0%... More of this article »
Image about Celestica Inc. (TSE:CLS) Receives C$388.33 Average Target Price from Analysts

Celestica Inc. (TSE:CLS) Receives C$388.33 Average Target Price from Analysts

Shares of Celestica Inc. (TSE:CLS – Get Free Report) (NYSE:CLS) have been assigned an average recommendation of “Strong Buy” from the nine brokerages that are covering the company, Marketbeat reports. Two equities... More of this article »
Image about Comparing Generate Biomedicines (GENB) & The Competition

Comparing Generate Biomedicines (GENB) & The Competition

Generate Biomedicines (NASDAQ:GENB – Get Free Report) is one of 855 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Generate Biomedicines to similar... More of this article »